Association of 6-Thioguanine Nucleotide Levels and Inflammatory Bowel Disease Activity: A Meta-Analysis

Gastroenterology

Volumn 130, Issue 4, 2006, Pages 1047-1053

  Osterman, Mark T ^a   Kundu, Rabi ^b   Lichtenstein, Gary R ^a   Lewis, James D ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b GRADUATE HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; MERCAPTOPURINE; THIOGUANINE DERIVATIVE;

ARTICLE; CELL HETEROGENEITY; CLINICAL TRIAL; CONFIDENCE INTERVAL; CORRELATION ANALYSIS; DATA ANALYSIS; DIAGNOSTIC ACCURACY; DISEASE ACTIVITY; ENTERITIS; ERYTHROCYTE; HUMAN; MEDLINE; META ANALYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REMISSION; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW; TIME SERIES ANALYSIS;

EID: 33646011261     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2006.01.046     Document Type: Article

References (23)

1. Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol 43 (1992) 329-339
2. Brogan M., Hiserodt J., Oliver M., et al. The effect of 6-mercaptopurine on natural killer-cell activities in Crohn's disease. J Clin Immunol 5 (1985) 204-211
3. Tiede I., Fritz G., Strand S., et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest 111 (2003) 1133-1145
4. Pearson D.C., May G.R., Fick G.H., et al. Azathioprine and 6-mercaptopurine in Crohn's disease. a meta-analysis. Ann Intern Med 123 (1995) 132-142
5. Markowitz J., Grancher K., Kohn N., et al. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 119 (2000) 895-902
6. Zimm S., Collins J.M., Riccardi R., et al. Variable bioavailability of oral mercaptopurine. is maintenance chemotherapy in acute lymphoblastic leukemia being optimally delivered?. N Engl J Med 308 (1983) 1005-1009
7. Weinshilboum R.M., and Sladek S.L. Mercaptopurine pharmacogenetics. monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 32 (1980) 651-662
8. Achkar J.P., Stevens T., Easley K., et al. Indicators of clinical response to treatment with six-mercaptopurine or azathioprine in patients with inflammatory bowel disease. Inflamm Bowel Dis 10 (2004) 339-345
9. Belaiche J., Desager J.P., Horsmans Y., et al. Therapeutic drug monitoring of azathioprine and 6-mercaptopurine metabolites in Crohn's disease. Scand J Gastroenterol 36 (2001) 71-76
10. Wright S., Sanders D.S., Lobo A.J., et al. Clinical significance of azathioprine active metabolite concentrations in inflammatory bowel disease. Gut 53 (2004) 1123-1128
11. Dubinsky M.C., Lamothe S., Yang H.Y., et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 118 (2000) 705-713
12. Goldenberg B.A., Rawsthorne P., and Bernstein C.N. The utility of 6-thioguanine metabolite levels in managing patients with inflammatory bowel disease. Am J Gastroenterol 99 (2004) 1744-1748
13. Hindorf U., Lyrenas E., Nilsson A., et al. Monitoring of long-term thiopurine therapy among adults with inflammatory bowel disease. Scand J Gastroenterol 39 (2004) 1105-1112
14. Mardini H.E., and Arnold G.L. Utility of measuring 6-methylmercaptopurine and 6-thioguanine nucleotide levels in managing inflammatory bowel disease patients treated with 6-mercaptopurine in a clinical setting. J Clin Gastroenterol 36 (2003) 390-395
15. Dubinsky M.C., Yang H.Y., Hassard P.V., et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 122 (2002) 904-915
16. Cuffari C., Hunt S., and Bayless T. Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise therapy in patients with inflammatory bowel disease. Gut 48 (2001) 642-646
17. Gupta P., Gokhale R., and Kirschner B. 6-Mercaptopurine metabolite levels in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 33 (2001) 450-454
18. Lowry P.W., Franklin C.L., Weaver A.L., et al. Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease. Gut 49 (2001) 665-670
19. Cuffari C., Theoret Y., Latour S., et al. 6-Mercaptopurine metabolism in Crohn's disease. correlation with efficacy and toxicity. Gut 39 (1996) 401-406
20. Lennard L., and Singleton H.J. High-performance liquid chromatographic assay of the methyl and nucleotide metabolites of 6-mercaptopurine. quantitation of red blood cell 6-thioguanine nucleotide, 6-thioinosinic acid and 6-methylmercaptopurine metabolites in a single sample. J Chromatogr B Biomed Sci Appl 83 (1992) 83-90
21. Roblin X., Serre-Debeauvais F., Heluwaert F., et al. A 6-TGN level superior to 250 pmoles/8 × 108 RBC under azathioprine is of clinical interest in patients with Crohn's disease or ulcerative colitis. Gastroenterology 126 (2004) A213
22. Bourreille A., Doubremelle M., Ganiere C., et al. Should 6-thioguanine nucleotides be monitored in patients with inflammatory bowel disease treated by azathioprine. Gastroenterology 124 (2003) A194
23. Roblin X., Serre-Debeauvais F., Phelip J.-M., et al. 6-Thioguanine monitoring in steroid-dependent patients with inflammatory bowel disease receiving azathioprine. Aliment Pharmacol Ther 21 (2005) 829-839